Radionuclides with alpha emitters plays a significant role in treating cancers in the field of therapeutic radiopharmaceuticals. Some properties such as short range and deposited energy in unit length of pathway augment the effect of alpha particle in destroying the DNA of cancer cells. Therefore, recognizing this capacity involves more investigations over the biological effect of these particles on human body. Properties of alpha emitters has led to exert profound differences between this field and other fields of nuclear medicine. Due to their short range and high LET (deposit energy in unit length of their pathway), alpha particles have remarkably been considered into medical research.
The report analyses the global alpha emitters market based on radionuclide type, medical application, end user and geography. Various radionuclide type studied are segmented into Actinium (Ac-225), Astatine (At-211), Bismuth (Bi -213), Bismuth (Bi-212), Lead (Pb-212), Radium (Ra-223) and Terbium (Tb-149). The medical application segment is categorized into prostate cancer, bone metastases, ovarian cancer, pancreatic cancer, endocrine tumors and others. Furthermore, the major end users considered in the study are hospitals, clinics and research laboratories. The global market is studied for the key regions such as, North America, Europe, Asia Pacific and Rest of the World.
Increase in awareness of the potential benefits of targeted alpha emitter and high number of patients with various types of cancers such as ovarian cancer, pancreatic cancer, lymphoma, and melanoma are likely to augment market growth.
Alpha emitter therapy holds a great promise when compared to chemotherapy as targeted alpha therapy allows easy discrimination between the healthy cells and cancer cells, and hence are effectively used for treatment of cancers including ovarian cancer, pancreatic cancer etc.
In addition, increasing use of targeted anticancer or alpha therapy (TAT) in the treatment of cancer and alpha particles has an advantage in targeted therapy because of their exceptionally high cell-killing ability. Ovarian cancer uses radio immunotherapy as locally injected adjuvant therapy.
Owing to the fact that the increase in oncology and neurological chronic diseases is the major driving factor for the market growth in the NA region. Moreover, the Asia Pacific alpha emitters market is anticipated to grow at a fastest growth rate during the forecast period. Over the forecast period, the phenomenon anticipated to boost market expansion, is the rise in number of healthcare facilities and improvement in care provision.
The major players operating in the alpha emitter market include Actinium Pharmaceuticals (United States), Alpha Tau Medical (Israel), Bayer AG (Germany), Fusion Pharmaceuticals Inc. (Canada), IBA RadioPharma Solutions (Belgium), Orano Med (France), Plexus Corp. (Columbia), RadioMedix, Inc. (United States) and Telix Pharmaceuticals Ltd (Australia).
Browse for more details: https://www.axiommrc.com/product/1717-alpha-emitters-market-report
3 Germay Dr.Ste 4 - 4666
Wilmington DE 19804
U.S.:- + 1 (845) 875-9786
U.K.:- + 44 (0) 20 3286 9707